Effects of resveratrol supplementation on bone biomarkers: a systematic review and meta‐analysis

  title={Effects of resveratrol supplementation on bone biomarkers: a systematic review and meta‐analysis},
  author={Marzieh Asis and Niloufar Hemmati and Sajjad Moradi and Kalyan C. Nagulapalli Venkata and Elham Mohammadi and Mohammad Hosein Farzaei and Anupam Bishayee},
  journal={Annals of the New York Academy of Sciences},
The current study presents a comprehensive systematic review and meta‐analysis of randomized controlled trials (RCTs) on resveratrol and bone health biomarkers. PubMed, Scopus, and Web of Science (until September 2018) were searched to identify the potential RCTs with information on resveratrol supplementation and bone metabolism biomarkers. Mean differences (MD) were analyzed using a random‐effects model. Pooling six RCTs (eight treatment arms with 264 subjects) together identified no… Expand
5 Citations
Effects of resveratrol supplementation on bone quality: a systematic review and meta-analysis of randomized controlled trials
  • Qiangqiang Li, Guangpu Yang, Hongtao Xu, Shaowen Tang, Wayne Yuk-wai Lee
  • Medicine
  • BMC Complementary Medicine and Therapies
  • 2021
Subgroup analysis showed the effect of resveratrol supplementation on BMD and serum bone markers were similar in trails of different doses, intervention duration, and pathological conditions of the participants. Expand
Effect of Chlorella vulgaris on Liver Function Biomarkers: a Systematic Review and Meta-Analysis
It seems that C. vulgaris supplementation mainly affects AST levels rather than ALT and ALP levels, however, as mentioned the effect of C. Vulgaris on those enzymes might be context-dependent and further investigations with a large number of patients as well as on different disorders are necessary and can provide more definitive evidence. Expand
The effects of resveratrol supplementation in patients with type 2 diabetes, metabolic syndrome, and nonalcoholic fatty liver disease: an umbrella review of meta-analyses of randomized controlled trials.
Current evidence does not support supplementation with resveratrol for the management of cardiometabolic risk factors in patients with T2D, MetS, and NAFLD. Expand
Nutritional Supplements and Skeletal Health
The effect size of nutrient interventions are relatively small, requiring large sample sizes for trials with bone outcomes, may be difficult to blind, and the impact of supplementation may depend on baseline intake, however, nutrition is the only intervention that can be implemented life long and on a population wide basis. Expand
Histone Acetylation in the Epigenetic Regulation of Bone Metabolism and Related Diseases
The results showed that acetylation connects a lot with bone metabolism, while the explorations about related metabolites like acetyl-CoA or different environmental exposures are still limited. Expand


Effect of resveratrol on blood pressure: A systematic review and meta-analysis of randomized, controlled, clinical trials
The favourable effect of resveratrol emerging from the current meta-analysis suggests the possible use of this nutraceutical as active compound in order to promote cardiovascular health, mostly when used in high daily dose (≥300 mg/day) and in diabetic patients. Expand
Short-term resveratrol supplementation stimulates serum levels of bone-specific alkaline phosphatase in obese non-diabetic men
Plasma levels of bone-specific alkaline phosphatase increased significantly in the resveratrol group as compared to placebo, and plasma levels ofBone metabolism parameters and circulating hormones were measured before and after the intervention period. Expand
Resveratrol increases bone mineral density and bone alkaline phosphatase in obese men: a randomized placebo-controlled trial.
It is suggested that high-dose RSV supplementation positively affects bone, primarily by stimulating formation or mineralization, in men with MetS and populations at risk of osteoporosis. Expand
Safety and metabolic outcomes of resveratrol supplementation in older adults: results of a twelve-week, placebo-controlled pilot study
It is suggested that short-term resveratrol supplementation at doses of 300mg/day and 1000mg/ day does not adversely affect blood chemistries and is well tolerated in overweight, older individuals. Expand
Association Between Dietary Intake of Antioxidants and Prevalence of Femoral Head Cartilage Defects and Bone Marrow Lesions in Community-based Adults
The findings suggest that the modification of dietary antioxidant intake may be a strategy for the prevention of hip OA, and higher Vitamin E intake was associated with reduced risk of hip cartilage defects. Expand
Osteogenic effects of resveratrol in vitro: potential for the prevention and treatment of osteoporosis
An overview of current research on resveratrol and its effects on bone cells in vitro is provided, highlighting the challenges and opportunities facing this area of research, especially in the context of providing nutritional support for postmenopausal women who may not benefit from HRT and older patients with various forms of arthritis, metabolic bone disease, and osteoporosis. Expand
Resveratrol supplementation affects bone acquisition and osteoporosis: Pre-clinical evidence toward translational diet therapy.
  • J. Tou
  • Medicine
  • Biochimica et biophysica acta
  • 2015
In the absence of human clinical trials, evidence for a role of RES on bone heath relies on evidence generated by animal studies, and a better understanding of efficacy, safety, and molecular mechanisms of RES will contribute to the determination of dietary recommendations and therapies to reduce osteoporosis. Expand
Prevalence of osteoporosis in China: a meta-analysis and systematic review
The prevalence of osteoporosis in China has increased over the past 12 years, affecting more than one-third of people aged 50 years and older, and three-step prevention programmes should be implemented. Expand
Bone turnover biomarkers and risk of osteoporotic hip fracture in an Asian population.
It is demonstrated that higher serum levels of bone turnover biomarkers were associated with increased risk of hip fracture in an Asian population. Expand
Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease
In this placebo-controlled, high-dose and long-term study, resveratrol treatment had no consistent therapeutic effect in alleviating clinical or histological NAFLD, though there may be a small ameliorating effect on liver function tests and liver fat accumulation. Expand